Publication | Closed Access
Successful Coronary Interventions Performed with Argatroban Anticoagulation in Patients with Heparin-Induced Thrombocytopenia and Thrombosis Syndrome.
31
Citations
0
References
1996
Year
ImmunologyPharmacotherapyThrombosisVenous ThrombosisStrokeHematologyPlatelet AntagonistHit AntibodyAtherosclerosisCardiologyHeparinsArgatroban AnticoagulationPercutaneous Coronary InterventionVascular BiologyHeparin-induced ThrombocytopeniaCardiovascular DiseaseBlood PlateletCoagulopathyThrombosis SyndromeMedicineAnticoagulantEmergency MedicineAnesthesiology
Patients with heparin-induced thrombocytopenia and thrombosis syndrome (HITTS) frequently have coincident vascular disease. Patients with HITTS who require vascular procedures have often been excluded from vascular intervention because intravascular procedures require heparin. Re-exposure to heparin places these patients at great risk for reactivation of thrombosis related to HIT antibody. We present our initial experience with an alternative anticoagulant to heparin, argatroban in patients with HIT antibody who underwent 14 coronary interventions. All 14 coronary lesions were treated successfully and no patient suffered an HITTS-related or an argatroban-related complication.